Comparative evaluation of Nigella sativa (Kalonji) and simvastatin for the treatment of hyperlipidemia and in the induction of hepatotoxicity

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 2, 2015, Pages 493-498

  Kirn E Muneera, K ^a   Majeed, Asifa ^a   Naveed, Abdul Khaliq ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

ALT; HDL C; LDL C; Nigella sativa; Simvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLACK CUMIN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFICACY; HYPERLIPIDEMIA; LIVER TOXICITY; NONHUMAN; PLANT SEED; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG-INDUCED LIVER INJURY; HYPERLIPIDEMIAS; PHYTOTHERAPY; SPRAGUE DAWLEY RAT;

ALANINE TRANSAMINASE; ANIMALS; CHOLESTEROL; DRUG-INDUCED LIVER INJURY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; NIGELLA SATIVA; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TRIGLYCERIDES;

EID: 84924959460     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Abisi S, Burnand KG, Humphries J, Waltham M, Taylor P and Smith A (2008). Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br. J. Surg., 95: 333-7.
2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B and Anand P (2008). Potential of spice-derived phytochemicals for cancer prevention. Planta Med., 74: 1560-9.
3. Ali BH and Blunden G (2003). Pharmacological and toxicological properties of Nigella sativa. Phytother. Res., 17: 299-305.
4. Armitage J, Bowman L, Collins R, Parish S and Tobert J (2009). Effects of simvastatin 40mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20, 536 high-risk people. BMC Clin. Pharmacol., 9: 6.
5. Asbach P, Paetsch I, Stawowy P, Sander B and Fleck E (2009). Statin-associated focal myositis. Int. .J Cardiol., 133: 33-4.
6. Ashraf SS, Rao MV, Kaneez FS, Qadri S, Al-Marzouqi AH, Chandranath IS and Adem A (2011). Nigella sativa extract as a potent antioxidant for petro chemicalinduced oxidative stress. J. Chromatog. Sci., 49: 321-6.
7. Attia AM, El-Banna SG, Nomeir FR and Abd El-Basser MI (2011). Lindane-induced biochemical perturbations in rat serum and attenuation by omega-3 and Nigella sativa seed oil. Indian. J. Biochem. Biophys., 48: 184- 90.
8. Avula B, Wang YH, Ali Z and Khan IA (2010). Quantitative determination of chemical constituents from seeds of Nigella sativa L. using HPLC-UV and identification by LC-ESI-TOF. J. AOAC. Int., 93: 1778-1787.
9. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH and Mohammad RM (2009). Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res., 69: 5575-5583.
10. Boskabady MH, Keyhanmanesh R, Khamneh S and Ebrahimi MA (2011). The effect of Nigella sativa extract on tracheal responsiveness and lung inflammation in ovalbumin-sensitized guinea pigs. Clinics (Sao Paulo)., 66: 879-887.
11. Cakmak H, Basar M, Seval-Celik Y, Osteen KG, Duleba AJ, Taylor HS, Lockwood CJ and Arici A (2012). Statins inhibit monocyte chemotactic protein 1 expression in endometriosis. Reprod. Sci., 19: 572-579.
12. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G and Badimon JJ (2005). Effects of aggressive versus conventional lipidlowering therapy by simvastatin on human atherosclerotic lesions: A prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol., 46: 106-12.
13. Dahri AH, Chandiol AM, Rahoo AA and Memon RA (2005). Effect of Nigella sativa (kalonji) on serum cholesterol of albino rats. J. Ayub Med. Coll., 17:72-74.
14. Falk E (2006). Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol., 47: 7-12.
15. Friedewald WT, Levy RI and Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18: 499-502.
16. Gheita TA and Kenawy SA (2012). Effectiveness of Nigella sativa oil in the management of rheumatoid arthritis patients: A placebo controlled study. Phytother. Res., 26; 1246-1248.
17. Kaatabi H, Bamosa AO, Lebda FM, Al Elq AH and Al- Sultan AI (2012). Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients. J. Family Community Med., 19: 155-161.
18. Kanter M, Coskun O and Budancamanak M (2005). Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloridetreated rats. World J. Gastroenter., 11: 684-688.
19. Khan MA (1999). Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharm., 7: 15-35.
20. Kocyigit Y, Atamer Y and Uysal E (2009). The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats. Saudi Med. J., 30: 893-896.
21. Law MR, Wald NJ and Rudnicka AR (2003). Quantifying effect of statins on low-density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. B.M.J., 326: 1423.
22. Ma FX and Han ZC (2005). Statins, nitric oxide and neovascularization. Cardiovasc. Drug Rev., 23: 281- 92.
23. Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA and Al-Sawaf HA (2001). Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: Evidence for antioxidant effects of thymoquinone. Res. Commun. Mol. Pathol. Pharmacol., 110: 239-251.
24. Matos SL, De Paula H, Pedrosa ML, Dos Santos RC, De Oliveira EL, Chianca DA and Silva ME (2005). Dietary models for inducing hypercholesterolemia in rats. Brazil. Arch. Biol. Technol., 48: 203-209.
25. Michel CG, El-Sayed NS, Moustafa SF, Ezzat SM, Nesseem DI and El-Alfy TS (2011). Phytochemical and biological investigation of the extracts of Nigella sativa L. seed waste. Drug Test Anal., 3: 245-54.
26. Moosmann B and Behl C (2004). Selenoprotein synthesis and side-effects of statins. Lancet., 363: 892-894.
27. Mukhtar RY and Reckless JP (2005). Statin-induced myositis: A commonly encountered or rare side effect. Curr. Opin. Lipidol., 16: 640-647.
28. Qidwai W, Hamza HB, Qureshi R and Gilani A (2009). Effectiveness, safety and tolerability of powdered Nigella sativa (kalonji). seed in capsules on serum lipid levels, blood sugar, blood pressure and body weight in adults: Results of a randomized, double-blind controlled trial. J. Altern. Complement. Med., 15: 639- 644.
29. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M, Hussain R, Cassim F, Nortje M, Vandehoven G and Temmerman AM (2011). CEPHEUS SA: A South African survey on the under treatment of Hyper cholesterolaemia. Cardiovasc. J. Afr., 22: 234- 240.
30. Ramadan MF and Morsel JT (2002). Characterization of phospholipid composition of black cumin (Nigella sativa L.) seed oil. Nahrung., 46: 240-244.
31. Sabzghabaee AM, Dianatkhah M, Sarrafzadegan N, Asgary S and Ghannadi A (2012). Clinical evaluation of Nigella sativa seeds for the treatment of hyper lipidemia: A randomized, placebo controlled clinical trial. Med. Arh., 66: 198-200.
32. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP and Ebrahim S (2011). Statins for the primary prevention of cardiovascular disease. Cochrane. Database. Syst. Rev., CD004816.
33. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, Mcalister FA, Wiebe N, Manns B and Alberta Kidney Disease N (2011). Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. C.M.A.J., 183: 1189-1202.
34. Winkelmayer WC, Asslaber M, Bucsics A, Burkhardt T, Schautzer A, Wieninger P, Pogantsch M, Brookhart MA and Pharmacoeconomics Advisory Council of the Austrian Sickness F (2010). Impact of reimbursement changes on statin use among patients with diabetes in Austria. Wien. Klin. Wochen., 122: 89-94.